Chongyu Shao

Chongyu Shao

Auto-generated profile, based on publicly available information

Chongyu Shao

College of Basic Medical Science, Zhejiang Chinese Medical University Zhejiang Hangzhou China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2022 in Ageing Research Reviews
Verified
Journal Article
Closed access
WLWentao Li
Wentao Li
CSChongyu Shao
Chongyu Shao
HZHuifen Zhou
Huifen Zhou
HDHaixia Du
Haixia Du
HCHaiyang Chen
Haiyang Chen
YHYu He
Yu He


24 September 2022 in Cellular and Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
YFYijia Fangma
Yijia Fangma
HWHaitong Wan
Haitong Wan
CSChongyu Shao
Chongyu Shao
LJLiang Jin
Liang Jin
YHYu He
Yu He

28 February 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
QMQianping Mao
Qianping Mao
CSChongyu Shao
Chongyu Shao
HZHuifen Zhou
Huifen Zhou
LYLi Yu
Li Yu
YBYida Bao
Yida Bao
HWHaitong Wan
Haitong Wan
This study aimed to explore the mechanisms through which salvianolic acid B (Sal-B) exerts its effects during myocardial ischemia-reperfusion injury (MI/RI), aiming to demonstrate the potential pharmacological characteristics of Sal-B in the management of coronary heart disease. First, Sal-B-related targets and MI/RI-related genes were compiled from public databases. Subsequent functional enrichment analyses using the protein–protein interaction (PPI) network, gene ontology (GO), and the Kyoto Encyclopedia of Genes and Genomes (KEGG) predicted the core targets and approaches by which Sal-B counters MI/RI. Second, a Sal-B-treated MI/RI mouse model and oxygen–glucose deprivation/reoxygenation (OGD/R) H9C2 cell model were selected to verify the main targets of the network pharmacological prediction. An intersectional analysis between Sal-B and MI/RI targets identified 69 common targets, with a PPI network analysis highlighting caspase-3, c-Jun N-terminal kinase (JNK), and p38 mitogen-activated protein kinase (p38) as central targets. GO and KEGG enrichment analyses indicated remarkable enrichment of the apoptosis pathway among these targets, suggesting their utility in experimental studies in vivo. Experimental results demonstrated that Sal-B treatment not only mitigated myocardial infarction size following MI/RI injury in mice but also modulated the expression of key apoptotic regulators, including Bcl-2-Associated X (Bax), caspase-3, JNK, and p38, alongside enhancing the B-cell lymphoma-2 (Bcl-2) expression, thereby inhibiting myocardial tissue apoptosis. This study leveraged an integrative network pharmacology approach to predict Sal-B’s potential targets in MI/RI treatment and verified the involvement of key target proteins within the predicted signaling pathways through both in vivo and in vitro experiments, offering a comprehensive insight into Sal-B’s pharmacological mechanism in MI/RI management.

1 July 2021 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
YPYuming Pan
Yuming Pan
CSChongyu Shao
Chongyu Shao
LZLing Zhang
Ling Zhang
YHYu He
Yu He
JYJintao Yang
Jintao Yang
HWHaitong Wan
Haitong Wan

12 August 2025 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
QLQiaomei Lou
Qiaomei Lou
LYLi Yu
Li Yu
SLSiyu Liu
Siyu Liu
CSChongyu Shao
Chongyu Shao
HWHaitong Wan
Haitong Wan
YHYu He
Yu He